Paola Valentino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1371843/publications.pdf

Version: 2024-02-01

90 2,471 29 45
papers citations h-index g-index

91 91 91 4074 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line. Current Issues in Molecular Biology, 2022, 44, 1247-1256.	2.4	4
2	The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes. Molecular Biology Reports, 2022, 49, 4709-4718.	2.3	3
3	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	7.6	38
4	Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells. Multiple Sclerosis and Related Disorders, 2022, 60, 103740.	2.0	10
5	CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab. International Journal of Environmental Research and Public Health, 2021, 18, 8163.	2.6	10
6	Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. Multiple Sclerosis and Related Disorders, 2021, 54, 103090.	2.0	13
7	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 914-920.	1.9	5
8	Headache due to intracranial hypertension at the time of first manifestation of multiple sclerosis. Neurological Sciences, 2020, 41, 491-492.	1.9	0
9	Focal neuromyotonia associated with a <i>C9ORF72</i> expansion mutation. Muscle and Nerve, 2020, 62, E63-E65.	2.2	1
10	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	3.6	19
11	Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered?. Infezioni in Medicina, 2020, 28, 258-262.	1.1	3
12	Evaluation of machine learning algorithms performance for the prediction of early multiple sclerosis from resting-state FMRI connectivity data. Brain Imaging and Behavior, 2019, 13, 1103-1114.	2.1	56
13	A multicenter retrospective study of charcotâ€marieâ€tooth disease type 4B (CMT4B) associated with mutations in myotubularinâ€related proteins (MTMRs). Annals of Neurology, 2019, 86, 55-67.	5.3	35
14	Assessment of the Corticospinal Tract Profile in Pure Lower Motor Neuron Disease: A Diffusion Tensor Imaging Study. Neurodegenerative Diseases, 2019, 19, 128-138.	1.4	6
15	A case of facioscapulohumeral muscular dystrophy and myasthenia gravis with positivity of anti-Ach receptor antibody: a fortuitous association?. Neurological Sciences, 2019, 40, 195-197.	1.9	7
16	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	3.6	20
17	Impairment of acquired color vision in multiple sclerosis: an early diagnostic sign linked to the greatness of disease. International Ophthalmology, 2019, 39, 671-676.	1.4	4
18	Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment. Multiple Sclerosis and Related Disorders, 2018, 20, 6-8.	2.0	12

#	Article	IF	CITATIONS
19	Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e498.	6.0	81
20	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	3.5	26
21	Exosomeâ€essociated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. FASEB Journal, 2018, 32, 4241-4246.	0.5	86
22	Multimodal assessment of normal-appearing corpus callosum is a useful marker of disability in relapsing–remitting multiple sclerosis: an MRI cluster analysis study. Journal of Neurology, 2018, 265, 2243-2250.	3.6	9
23	Camptocormia as presenting in lower motor neuron disease with TARDBP mutation: case report. Neurological Sciences, 2017, 38, 1885-1887.	1.9	4
24	Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients. Journal of Immunological Methods, 2017, 445, 53-58.	1.4	10
25	Aquaporin-4 antibody titration in NMO patients treated with rituximab. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e317.	6.0	53
26	The corticospinal tract profile in amyotrophic lateral sclerosis. Human Brain Mapping, 2017, 38, 727-739.	3.6	54
27	Superior Cerebellar Peduncle Atrophy Predicts Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients with Cerebellar Symptoms: A DTI Study. Journal of Multiple Sclerosis, 2017, 04, .	0.1	2
28	Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients. Multiple Sclerosis Journal, 2016, 22, 1094-1105.	3.0	24
29	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0120754.	2.5	31
30	Structural â€~connectomic' alterations in the limbic system of multiple sclerosis patients with major depression. Multiple Sclerosis Journal, 2015, 21, 1003-1012.	3.0	49
31	The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing–remitting multiple sclerosis. NeuroImage: Clinical, 2015, 7, 28-33.	2.7	24
32	Biological monitoring of IFN- \hat{l}^2 therapy in Multiple Sclerosis. Cytokine and Growth Factor Reviews, 2015, 26, 241-248.	7.2	16
33	Anti-GAD-associated inflammatory myopathy presenting with dropped head syndrome. Neurological Sciences, 2015, 36, 1517-1519.	1.9	3
34	CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study. Journal of Neuroimmunology, 2014, 277, 127-133.	2.3	5
35	Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Multiple Sclerosis Journal, 2014, 20, 220-226.	3.0	30
36	Tractography in amyotrophic lateral sclerosis using a novel probabilistic tool: A study with tract-based reconstruction compared to voxel-based approach. Journal of Neuroscience Methods, 2014, 224, 79-87.	2.5	43

#	Article	IF	CITATIONS
37	Diffusion tensor MRI changes in gray structures of the frontal-subcortical circuits in amyotrophic lateral sclerosis. Neurological Sciences, 2014, 35, 911-918.	1.9	17
38	Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. Journal of Neurology, 2014, 261, 2159-2164.	3.6	59
39	MR imaging and cognitive correlates of relapsing–remitting multiple sclerosis patients with cerebellar symptoms. Journal of Neurology, 2013, 260, 1358-1366.	3.6	28
40	Computer-Assisted Cognitive Rehabilitation of Attention Deficits for Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2013, 27, 284-295.	2.9	131
41	The BDNF Val66Met Polymorphism Has Opposite Effects on Memory Circuits of Multiple Sclerosis Patients and Controls. PLoS ONE, 2013, 8, e61063.	2.5	21
42	A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, 90.	0.4	5
43	Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology, 2012, 79, 2315-2320.	1.1	70
44	Cerebellar-parietal dysfunctions in multiple sclerosis patients with cerebellar signs. Experimental Neurology, 2012, 237, 418-426.	4.1	24
45	Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-Î ³ and interleukin-4 response. Multiple Sclerosis Journal, 2012, 18, 1484-1492.	3.0	2
46	FUS mutations in sporadic amyotrophic lateral sclerosis: Clinical and genetic analysis. Neurobiology of Aging, 2012, 33, 837.e1-837.e5.	3.1	32
47	Blink reflex recovery cycle in patients with essential tremor associated with resting tremor. Neurology, 2012, 79, 1490-1495.	1.1	34
48	Evaluation of a Multiparametric Immunofluorescence Assay for Standardization of Neuromyelitis Optica Serology. PLoS ONE, 2012, 7, e38896.	2.5	19
49	A Cellular Neural Network methodology for the automated segmentation of multiple sclerosis lesions. Journal of Neuroscience Methods, 2012, 203, 193-199.	2.5	44
50	NOS2A as a candidate gene in Relapsing–Remitting Multiple Sclerosis: A haplotype study using selected subsets of single nucleotide polymorphisms. Journal of the Neurological Sciences, 2011, 304, 75-77.	0.6	2
51	Synchronous pattern distinguishes resting tremor associated with essential tremor from rest tremor of Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 30-33.	2.2	53
52	Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report. Journal of Neurology, 2011, 258, 1349-1350.	3.6	17
53	Histopathological, clinical, and electrophysiological features influencing postoperative outcomes in carpal tunnel syndrome. Journal of Orthopaedic Research, 2011, 29, 1298-1304.	2.3	16
54	Leber's hereditary optic neuropathy associated with a multiple-sclerosis-like picture in a man. Multiple Sclerosis Journal, 2011, 17, 763-766.	3.0	15

#	Article	IF	CITATIONS
55	Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. Journal of Neuroimmunology, 2010, 225, 175-179.	2.3	25
56	Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis. PLoS ONE, 2010, 5, e8962.	2.5	69
57	The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: An imaging genetic study. Behavioural Brain Research, 2010, 207, 377-386.	2.2	42
58	An Axon Regeneration Signature in a Charcot-Marie-Tooth Disease Type 2 Patient. Journal of Neurogenetics, 2009, 23, 324-328.	1.4	4
59	Cognitive deficits in multiple sclerosis patients with cerebellar symptoms. Multiple Sclerosis Journal, 2009, 15, 854-859.	3.0	52
60	Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. Brain, 2009, 132, 3380-3391.	7.6	96
61	Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 114-115.	3.0	7
62	Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study. Multiple Sclerosis Journal, 2009, 15, 204-211.	3.0	16
63	CASP-9: A susceptibility locus for multiple sclerosis in Italy. Journal of Neuroimmunology, 2009, 210, 100-103.	2.3	12
64	A longitudinal observation of Brain-Derived Neurotrophic Factor mRNA levels in patients with Relapsing–Remitting Multiple Sclerosis. Brain Research, 2009, 1256, 123-128.	2.2	28
65	An exploration of anger phenomenology in multiple sclerosis. European Journal of Neurology, 2009, 16, 1312-1317.	3.3	16
66	Neurofunctional correlates of personality traits in relapsing-remitting multiple sclerosis: An fMRI study. Brain and Cognition, 2009, 71, 320-327.	1.8	19
67	Further evidence that D90A-SOD1 mutation is recessively inherited in ALS patients in Italy. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 58-60.	2.1	10
68	Orolingual tremor as unusual presentation of antiâ€Hu paraneoplastic syndrome. Movement Disorders, 2008, 23, 1791-1792.	3.9	6
69	Genetic screening for familial amyloid polyneuropathy in patients with idiopathic carpal tunnel syndrome. Journal of the Peripheral Nervous System, 2008, 13, 151-152.	3.1	2
70	Preliminary evidences of a NOS2A protective effect from Relapsing–Remitting Multiple Sclerosis. Journal of the Neurological Sciences, 2008, 264, 112-117.	0.6	7
71	Somatosensory evoked potentials reflect the upper limb motor performance in multiple sclerosis. Journal of the Neurological Sciences, 2008, 273, 99-102.	0.6	9
72	A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. Neuromuscular Disorders, 2008, 18, 68-70.	0.6	46

#	Article	IF	CITATIONS
73	A case of acute quadriplegia complicating Mediterranean spotted fever. Clinical Neurology and Neurosurgery, 2007, 109, 463-465.	1.4	11
74	Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. Journal of the Neurological Sciences, 2007, 263, 15-19.	0.6	130
75	Two-dimensional gel electrophoresis of peripheral nerve proteins: Optimized sample preparation. Journal of Neuroscience Methods, 2007, 159, 125-133.	2.5	7
76	Impact of individual cognitive profile on visuo-motor reorganization in relapsing–remitting multiple sclerosis. Brain Research, 2007, 1167, 71-79.	2.2	22
77	The role of VLA4 polymorphisms in multiple sclerosis: An association study. Journal of Neuroimmunology, 2007, 189, 125-128.	2.3	9
78	Anti-interferon- \hat{l}^2 neutralising activity is not entirely mediated by antibodies. Journal of Neuroimmunology, 2007, 192, 198-205.	2.3	22
79	Qualitative and quantitative analysis of antibody response against ${\sf IFN}\hat{\sf I}^2$ in patients with multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 738-746.	3.0	18
80	Adaptive cortical changes and the functional correlates of visuo-motor integration in relapsing-remitting multiple sclerosis. Brain Research Bulletin, 2006, 69, 597-605.	3.0	30
81	Sporadic ALS is not associated with VAPB gene mutations in Southern Italy. Journal of Negative Results in BioMedicine, 2006, 5, 7.	1.4	19
82	Genetic heterogeneity in patients with pantothenate kinase–associated neurodegeneration and classic magnetic resonance imaging eye-of-the-tiger pattern. Movement Disorders, 2006, 21, 252-254.	3.9	26
83	Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 77-87.	3.0	119
84	Gene conversion events in adult-onset spinal muscular atrophy. Acta Neurologica Scandinavica, 2004, 109, 151-154.	2.1	12
85	Temporal Lobe Epilepsy as a Unique Manifestation of Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2003, 30, 228-232.	0.5	36
86	Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sj�gren syndrome. Annals of Neurology, 2000, 47, 260-264.	5.3	40
87	Autosomal Recessive Hereditary Motor and Sensory Neuropathy with Focally Folded Myelin Sheaths (CMT4B). Annals of the New York Academy of Sciences, 1999, 883, 47-55.	3.8	16
88	Spinal muscular atrophy due to an isolated deletion of exon 8 of the telomeric survival motor neuron gene. Annals of Neurology, 1998, 44, 836-839.	5.3	32
89	CAG repeat length and clinical features in three Italian families with spinocerebellar ataxia type 2 (SCA2): early impairment of Wisconsin Card Sorting Test and saccade velocity. Journal of Neurology, 1998, 245, 647-652.	3.6	59
90	Action palatal tremor in a patient with primary intestinal lymphoma. Movement Disorders, 1997, 12, 794-797.	3.9	12